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Disruption of viral latency in Epstein-Barr virus-infected cells is mediated through the activation of the
BZLF1 (Z) immediate-early gene product. The Z protein can be derived from either of two promoters: the
BZLF1 promoter, which directs transcription of a 1.0-kb mRNA encoding the Z gene product alone, or the
upstream BRLF1 promoter, which directs transcription of a 2.8-kb bicistronic mRNA encoding the BRLF1 and
BZLF1 immediate-early proteins. In this study we have examined the regulation of the BRLF1 promoter by
viral and cellular factors. We found that the BRLF1 promoter is autoregulated by the BRLF1 transactivator
through a nonbinding mechanism. We show that the BRLF1 (but not the BZLF1) promoter is highly responsive
to the Spl transcription factor. Spl activation of the BRLF1 promoter is mediated through a consensus
Spl-binding site located from -39 to -44 (relative to the mRNA start site). We demonstrate that the BRLF1
promoter has high constitutive activity in C-33 cells (an epithelial cell line) and that the proximal Spl-binding
site is required for this activity. Despite the ubiquitous presence of Spl in many cell types, we found that the
BRLF1 promoter has essentially no activity in lymphoid cell lines, suggesting that factors other than Spl may
negatively regulate the BRLF1 promoter in these cells. Our findings demonstrate that the two potential
promoters directing BZLF1 transcription are differentially regulated and that Spl can activate the BRLF1
promoter but not the BZLF1 promoter.
Epstein-Barr virus (EBV) is a human herpesvirus which
infects both epithelial and lymphoid cells (38). Infection of
epithelial cells can lead to nasopharyngeal carcinoma (56,
72), whereas infection of B cells is associated with Burkitt's
lymphoma and B-cell lymphoma (52, 72). EBV infection of
epithelial cells is often associated with productive viral
expression (43, 64). In contrast, EBV infection of B cells is
generally latent, although overexpression of the EBV imme-
diate-early (IE) gene product, BZLF1 (Z), is sufficient to
disrupt latency (8-10, 57, 58, 66). The cellular control of
BZLF1 transcription therefore plays a crucial role in the
disruption of viral latency.
The BZLF1 gene product can be derived from either of
two promoters (50). The more proximal (3') promoter,
BZLF1, drives transcription of a 1.0-kb mRNA which en-
codes only the BZLF1 gene product, whereas an upstream
promoter, BRLF1, drives transcription of a 2.8-kb bicis-
tronic mRNA which encodes both the BZLF1 and BRLF1
(R) gene products (2, 18, 50, 51, 65). The BZLF1 IE gene
product is a leucine zipper protein (71) which activates a
number of different early EBV promoters (8, 19, 37, 46, 47,
57, 68, 70) through a direct binding mechanism (5, 17, 19, 21,
25, 40, 45, 46, 57, 68, 70). The R IE protein is also a
transcriptional activator (6-8, 31, 36) and sequence-specific
DNA-binding protein (27, 28, 49). The combination of
BZLF1 and BRLF1 has been shown to induce synergistic
transactivation of several early EBV promoters (8, 13, 25,
32, 55).
It is not yet clear whether disruption of viral latency is
mediated primarily by activation of the BZLF1 promoter or
activation of the BRLF1 promoter. Sinclair et al. have
reported that the BZLF1 gene product can activate BRLF1
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promoter activity and have suggested that disruption of
latency may be mediated primarily at the BZLF1 promoter,
with the Z protein subsequently activating the BRLF1 pro-
moter (63). However, analyses of the time course of the
induction of the 1.0- and 2.8-kb mRNAs have shown that
they are both already present even at the earliest time points
assayed (51, 63). The Z gene product has been previously
shown to activate BZLF1 promoter expression (19). There-
fore, it is plausible that activation of the BRLF1 promoter
sometimes precedes activation of BZLF1 and that the result-
ant translation of the Z gene product from the bicistronic
2.8-kb mRNA subsequently activates BZLF1 promoter
function. Nevertheless, the ability of Z protein derived from
the bicistronic 2.8-kb mRNA to disrupt viral latency has
not yet been firmly documented. Regardless of which pro-
moter is activated first in the disruption of viral latency, the
BRLF1 promoter plays a key role because it is the only
promoter known to drive transcription of the R IE gene
product.
To date, we are aware of only one report which has been
published regarding the regulation of the BRLF1 promoter
(63). In this report the BRLF1 promoter was found to
contain two Z-binding sites and to be activated by both the
BZLF1 and BRLF1 viral IE transactivators (63). However,
nothing is known about the cellular regulation of BRLF1. In
the work described in this paper, we have studied the
regulation of the BRLF1 promoter by viral and cellular
factors. We show here that the cellular transcription factor,
Spl, strongly activates the BRLF1 promoter. Despite the
ubiquitous presence of Spl in all cell types, we found that
the BRLF1 promoter is inactive in B cells (in which EBV
infection tends to be latent) but quite active in C-33 cells (an
epithelial cell line). Therefore, the BRLF1 promoter is likely
to be negatively regulated by additional cellular factors.
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MATERIALS AND METHODS
Cell lines. The cell lines used include EBV-negative Bur-
kitt's lymphoma B-cell lines (Louckes and Ramos), the
Jurkat T-cell line, a latently infected EBV-positive B-cell
line (Raji), the cervical epithelial cell lines HeLa (papilloma-
virus positive) and C-33 (papillomavirus negative), the EBV-
positive epithelial cell line NPC-KT (67), and the Drosophila
embryo cell line Schneider line 2 (SL2) (62). All lymphoid
cell lines were maintained in RPMI 1640 medium supple-
mented with 10% fetal calf serum. All epithelial cell lines
were maintained in Dulbecco modified Eagle medium H
supplemented with 10% fetal calf serum. The Schneider line
2 (provided by C. Benyajati) was maintained in Drosophila
Schneider media obtained from GIBCO-BRL with 10% fetal
calf serum.
Plasmids. We initiated our studies by constructing a vector
(RpBSCAT) containing the presumed BRLF1 promoter se-
quences (from -959 to +11 relative to the mRNA start site)
linked to the heterologous reporter gene, chloramphenicol
acetyltransferase (CAT) in the pBS phagemid vector (Strat-
agene). Our promoter sequence was based on previously
published cDNA mapping which showed that the mRNA
start site of the bicistronic mRNA encoding the Z and R
transactivators was located at EBV sequence 106,175 (50). A
series of 5' deletions of this promoter was constructed by
cutting at convenient restriction sites and religating, as
shown in Fig. 1A.
Site-directed mutants of the BRLF1 promoter construct
(Fig. 1B) were made by using a Bio-Rad Muta Gene phage-
mid in vitro mutagenesis kit, which is based on the method of
Kunkel (41). Synthetic oligonucleotides complementary to
the region to be altered, except for a limited internal mis-
match, were designed. We introduced a new restriction site
in the oligonucleotide to screen for mutants.
The construction of the R and Z transactivating plasmids
has been previously described (32). The Z plasmid (pEBV-
ZIE) contains the BamHI Z gene fragment in the pGEM2-
based vector pHD1013 such that the BZLF1 gene is under
the control of the strong cytomegalovirus IE promoter. The
R plasmid (pEBV-RIE) contains the BRLF1 gene linked to
cytomegalovirus IE promoter in a pUC-based plasmid (32).
The plasmid pPacSpl (a gift from Robert Tjian) contains a
2.1-kb fragment encoding the C-terminal 696 amino acids of
Spl driven by the Drosophila actin promoter (12). As a
vector control for Spl transfection studies, we made a
frameshift mutation within the BamHI site of the Spl open
reading frame and named this plasmid pPacSplFX.
DNA transfections. Plasmid DNAwas purified through two
sequential cesium chloride gradients. DNA was transfected
in both lymphoid and epithelial cells by electroporation (69),
with 10 ,g of DNA and 107 cells per condition. Cells were
shocked at 1,500 V with a Zapper electroporation unit
(Medical Electronics Shop, University of Wisconsin). Epi-
thelial cells were harvested and suspended into RPMI 1640
medium prior to electroporation.
Schneider line 2 (SL2) cells were transfected by the
calcium phosphate precipitation method (15). Cells were
replated onto petri dishes at a density of 107 cells per plate 20
to 24 h before transfection. For each condition, 10 tg of
reporter CAT plasmid and 1 ,g of Spl expression plasmid
were used. The cells were harvested 48 h after addition of
DNA.
CAT assays. Cell extracts were prepared 48 h after trans-
fection and incubated at 37°C with [1 C]chloramphenicol in
the presence of acetyl coenzyme A as described previously
(26). The percent acetylation of chloramphenicol was quan-
titated by thin-layer chromatography followed by scintilla-
tion counting or AMBIS scanning (AMBIS, Inc.).
Gel mobility shift assays. Gel retardation studies were
performed as previously described (22, 24). Cellular nuclear
extracts were prepared by a modification of the method of
Dignam et al. (14). The binding reactions consisted of 20,000
cpm of 32P-end-labeled probes spanning the entire BRLF1
promoter incubated with 4p,g of nuclear extract in a buffer
consisting of 50 mM Tris (pH 7.9), 250 mM NaCl, 2.5 mM
EDTA, 5 mM dithiothreitol, 5mM MgCl2, and 50% glycerol.
Poly(dI-dC) poly(dI-dC) (4,ug) was added as a nonspecific
competitor DNA, and the final volume was adjusted to 20 pl.
The reaction mixture was loaded on a 4% polyacryl-
amide-1% Tris glycine gel and run inlx Tris glycine buffer
(0.025 M Tris, 0.19 M glycine) at 20 mA at room tempera-
ture. The gel was dried and subjected to autoradiography.
For studies of R protein binding, we used a bacterial
fusion protein (pGR356) containing the first 356 amino acids
of R ligated into the PGEX-3X vector as previously de-
scribed (29). The negative control vector, PGR-, contains
the R reading frame in an antisense orientation. These
plasmids were induced for 2 h in Escherichia coli DH5aF'
at 30°C with 1 mM isopropyl-,-D-thiogalactopyranoside
(IPTG). The bacteria were lysed by sonication in buffer
containing 50 mM KCI, 50 mM phenylmethylsulfonyl fluo-
ride, and 8,uM leupeptin. The samples were centrifuged, and
the supernatants were assayed for protein concentration (3)
prior to use in gel retardation studies. The R-binding reaction
consisted of 20,000 cpm of probe and 10p,g of GR356 or PGR
protein in a buffer consisting of 50 mM KCl, 10 mM N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES;
pH 7.3), 5% Ficoll, 5mM MgCl2, 0.5 mM dithiothreitol, and
0.5 mM phenylmethylsulfonyl fluoride and 1 ,ug of poly(dI-
dC). poly(dI-dC) in a final volume of 30 ,ul. The binding
reaction was incubated at 4°C for 15 min, and the reaction
mixture was loaded onto a 5% polyacrylamide gel and run in
0.5 x Tris borate buffer.
Methylation protection assays. Methylation protection was
performed by a modification of the methylation interference
procedure previously described (1). For these experiments,
the binding reaction consisted of 100,000 cpm of probe
incubated with 2 volumes of the reaction mixture used in gel
retardation assays described above. Just prior to loading on
a 4% polyacrylamide-1% Tris glycine gel, 1 pl of dimethyl
sulfate was added to the binding reaction. The bands repre-
senting the Spl bound (determined by competition assays)
and the free probe were cut separately from the gel and
transferred to DEAE membrane paper. The membrane was
incubated with 1 M piperidine at 90°C for 15 min and then
rinsed twice with 1 ml of sterile water. The probe fragments
were eluted from the membrane with 250 pl of elution buffer
consisting of 1 M NaCl, 0.1 mM EDTA, and 20 mM Tris (pH
8.0) at 67°C. Equal amounts of radioactive bound and free
probes were then loaded on a 6% polyacrylamide-7 M urea
gel and subjected to autoradiography.
RESULTS
The BRLF1 promoter is constitutively active in epithelial
cells but not in lymphoid cells. Our initial analysis of the
BRLF1 promoter sequence (Fig. 1) suggested that there is a
TATA box (CATAAAA) located 26 bp upstream of the RNA
start site. In addition, we noted that there is a consensus
Spl-binding site (CCGCCC) (4, 12, 16, 34) positioned at -39
bp relative to the start site and two copies of another
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FIG. 1. Construction of RpBS plasmids and 5' deletions. (A) The parental vector, RpBSCAT, contains the BRLF1 promoter sequences
(from -959 to +11 relative to the mRNA start site) linked to CAT in the pBS vector. The locations of three potential Spl-binding sites in the
BRLF1 promoter are indicated. A series of 5' deletions was constructed as shown. (B) A series of site-directed mutants of the RpBSCAT
vector was constructed as shown. The locations of the TATA box, the CCAAT box, and the proximal Spl motif are as indicated. The
previously mapped (63) proximal Z-binding site is underlined. The site-directed mutants are named to reflect the BRLF1 promoter sequences
(relative to the start site) affected.
sequence recently shown to bind Spl (CCACCC) (44) posi-
tioned at -272 and -490 bp. There is also a consensus
CCAAT box sequence (61) located between the TATA box
and the consensus Spl motif.
To study BRLF1 promoter function, we constructed the
vector RpBSCAT, as shown in Fig. 1, which contains the
BRLF1 promoter sequences from -959 to +11 (relative to
the mRNA start site) linked to the CAT reporter gene.
Initially we examined the level of constitutive BRLF1 pro-
moter activity in a variety of cell types. As a positive
control, we used the RSV-CAT construct (a gift from Bruce
Howard), which contains the Rous sarcoma virus long
terminal repeat linked to CAT and has strong promoter
activity in a variety of cell types (26). As a negative control,
we used the pBS-CAT construct, which is identical to the
RpBSCAT construct except that it contains no eukaryotic
promoter sequences.
The activity of the BRLF1 promoter construct in a variety
of cell types is shown in Fig. 2. The highest level of
constitutive BRLF1 promoter activity was observed in C-33
cells (a papillomavirus-negative cervical carcinoma cell
line). In this cell type, the BRLF1 promoter construct
(RpBSCAT) produced an average of 17% acetylation in CAT
assays incubated for 1 h, a value which was approximately















FIG. 2. Constitutive activity of the BRLF1 promoter in different
cell types. The activity of the CAT vector containing the BRLF1
promoter (RpBSCAT) (-) was compared with that of the positive
control vector containing the Rous sarcoma virus promoter (RSV-
CAT) (O) and that of the promoterless negative control vector,
pBSCAT (5) in different cell types. Cells were transfected with 5 ptg
of each plasmid and analyzed for CAT activity (in a 1-h incubation) 48
h after transfection as previously described (26). C-33, HeLa, and
NPC-KT are epithelial cell lines. Jurkat is a T-cell line. Louckes, Raji,
and P3HR1 are B-cell lines. The numbers are presented as average
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erless CAT vector, pBSCAT. In the two other epithelial
lines studied, the EBV-positive NPC-KT line and the EBV-
negative HeLa cell line, the level of RpBSCAT activity was
also greater than that of the negative control vector. How-
ever, in several different lymphoid cell types tested (the
T-cell line Jurkat, the EBV-negative B-cell line Louckes,
and the EBV-positive B-cell lines Raji and P3HR1), the level
of CAT activity produced by the RpBSCAT construct was
lower than that produced by the negative control construct.
Thus, it appears that the BRLF1 promoter may be subject to
negative regulation in lymphoid cells.
Effect of the Z transactivator on BRLF1 promoter activity.
We next examined the effect of the Z transactivator on
BRLF1 promoter activity in different cell types. Sinclair et
al. have previously reported that the BRLF1 promoter
contains two Z-binding sites (centered at -28 and -189) and
can be activated by cotransfection with the Z gene product
(63). However, the Z transactivation of the BRLF1 promoter
reported by these investigators was quite low (only a three-
fold effect in C-33 cells) compared with that of other Z-re-
sponsive promoters (8, 19, 37, 46, 47, 57, 68, 70). The results
of our own experiments comparing the effect of the Z
transactivator on the RpBSCAT construct with that on the
promoterless control vector, pBSCAT, in a variety of cell
types are shown in Fig. 3A. We were unable to document
significant activation of the BRLF1 promoter (with respect
to the negative control vector) in any cell type. In control
experiments (data not shown), as previously reported (32,
47), we could easily detect strong transactivation of the
BMRF1 and BHRF1 CAT constructs by the Z vector. It thus
appears that Z-induced transactivation of the BRLF1 pro-
moter is minimal in comparison with the effect of Z on the
BMRF1 and BHRF1 promoters or that such transactivation
may require a particular cellular environment or dosage of Z.
The R transactivator activates BRLF1 promoter activity
through a nonbinding mechanism. We also studied the effect
of the R transactivator on BRLF1 promoter activity. Sinclair
et al. have previously reported that the R transactivator
produces low-level (approximately fourfold) activation of
the BRLF1 promoter (63). This group did not investigate
whether the R protein can bind directly to the BRLF1
promoter. As shown in Fig. 3B, we likewise observed
increased BRLF1 promoter activity (in comparison with that
of the negative control vector, pBS-CAT) in the presence of
R in a variety of cell types. However, this R-induced
transactivation of the BRLF1 promoter is much lower than
the effect that we previously noted when using the EBV
early promoter, BMLF1 (36).
Because the R IE protein has been recently shown to be a
sequence-specific DNA-binding protein which binds directly
to the R-responsive BMLF1 and DR enhancer elements (27,
28, 49), we investigated the possibility that the low-level R
transactivation of the BRLF1 promoter is also mediated by a
direct binding mechanism. We used a bacterial fusion pro-
tein containing the first 356 amino acids of the R protein as a
source of protein and performed gel retardation assays with
various probes spanning the entire BRLF1 promoter (-1 to
-182, -48 to -390, and -390 to -959 bp). As a positive
control for R binding, we made a probe containing the
R-responsive region of the BMLF1 promoter (27). As shown
in Fig. 4, we observed R binding to the BMLF1 probe, which
was specifically inhibited (data not shown) by an oligonucle-
otide sequence containing another known R-binding site
from the DR enhancer element. However, using probes of
the BRLF1 promoter sequence region, we could not see any
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FIG. 3. Effect of the Z and R transactivators on BRLF1 pro-
moter function. (A) The RpBSCAT plasmid (5 Fg) (0) or the
promoterless negative control plasmid, pBSCAT (-), was cotrans-
fected with 5 p,g of either the pHD1013 vector DNA or the Z
transactivator plasmid (pEBV-ZIE). The average fold transactiva-
tion induced by the pEBV-ZIE plasmid (compared with that induced
by the pHD1013 vector DNA) is shown for different cell types. (B)
The average fold transactivation induced by the R transactivator
plasmid (pEBV-RIE) compared with vector DNA (pHD1013) in
cotransfections with pBSCAT (-) and RpBSCAT (0) is shown for
different cell types.
likely that the low-level R-induced transactivation of the
BRLF1 promoter is mediated through an indirect mecha-
nism.
The Spl transcription factor activates the BRLF1 promoter
but not the BZLF1 promoter. Because the BRLF1 promoter
contains several potential Spl-binding sites, as shown in Fig.
1, we next examined whether the cellular Spl transcription
factor can activate BRLF1 promoter function. Spl transfec-
tion studies were performed with SL2 cells as previously
reported (15), because these cells contain no endogenous
Spl activity. As shown in Fig. 5, the BRLF1 promoter was
highly responsive to the Spl transactivator. The simian virus
40 (SV40) early promoter construct, pAlOCAT (42), which
has six Spl-binding sites (16), served as a positive control
and, as expected, was also activated by the Spl expression
plasmid. In contrast, two other EBV promoters, the IE
BZLF1 promoter and the early BMRF1 promoter, were not
found to be significantly activated by Spl. These experi-
ments confirm that the Spl transcription factor specifically
activates the BRLF1, but not the BZLF1, IE EBV promoter.
Defining the Spl-responsive regions(s) in the BRLF1 pro-
VOL. 66, 1992





















FIG. 4. The R protein does not bind directly to the BRLF1
promoter. A bacterial fusion protein was constructed containing the
amino-terminal 356 amino acids of BRLF1 (which contains the
DNA-binding domain) in the pGEX-3X vector. The BRLF1 fusion
protein binds to a known R-binding site within the BMLF1 (27)
promoter as shown. This binding is specifically inhibited by an
oligonucleotide containing a known R-binding site in the DR en-
hancer (28) but not by the identical oligonucleotide in which the
R-binding sequence has been mutated (data not shown). The R
fusion protein does not bind to a probe containing the BRLF1
promoter sequences from -1 to -182 or additional BRLF1 probes
spanning the promoter sequences between -179 and -959 (data not
shown).
moter. We next examined which regions of the BRLF1
promoter are required for Spl responsiveness. We initially
cotransfected the series of 5' BRLF1 promoter deletion
mutants (Fig. 1A) into SL2 cells with the Spl expression
plasmid and measured the resultant increase in the BRLF1
promoter activity. In this series of experiments (Fig. 6), the
parent plasmid, RpBSCAT, was activated an average of
114-fold by cotransfection with Spl. When the promoter
sequences between -959 and -575 were deleted, Spl re-
sponsiveness was not decreased (in fact, Spl responsiveness
Spi+ Sp -t p,* SP.I
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FIG. 5. Effect of the Spl transcription factor on different EBV
promoters. Promoter constructs (10 pLg) containing either the
BRLF1 IE promoter (RpBSCAT), the SV40 early promoter
(pAlOCAT) (42), the EBV BZLF1 IE promoter (BZLF1-CAT) (37),
the EBV BMRF1 early promoter (BMRF1-CAT) (37), or the pro-
moterless CAT vector (pBSCAT) were cotransfected into Droso-
phila SL2 cells with either 1 jig of the Spl expression vector,
pPacSpl (12), or an equal amount of the pPacSplFX vector con-
taining a frameshift Spl mutation. The SV40 and BRLF1 promoters
were activated by the Spl transcription factor, whereas the BZLF1
and BMRF1 promoters were not affected. Repeat experiments gave
similar results.
increased to 139% of that of the parental construct). In
contrast, 80% of the Spl-induced transactivation was lost
when sequences between -575 and -379 were deleted. This
deleted region contains one potential Spl site. The Spl
responsiveness of the promoter was totally lost when the
promoter sequences between -182 and -33 (which contain
the consensus Spl-binding site) were deleted. These results
suggest that two regions of the BRLF1 promoter, one
located between -33 and -182 and the other located be-
tween -379 and -575, contribute to total Spl responsive-
ness.
A site-directed mutation of the proximal Spl-binding site
decreases Spl responsiveness. To examine more directly the
functional significance of the proximal Spl site, we intro-
duced a site-directed mutation in the proximal Spl site at
-39, leaving the rest of the promoter intact, as shown in Fig.
1B. In addition to the mutation specifically abolishing the
proximal Spl motif, we constructed several other site-
directed mutations in the BRLF1 promoter, as shown in Fig.
1B, and tested the ability of Spl to activate each of these
mutant constructs. As shown in Fig. 6, removal of the
proximal Spl site (positions -39 to -44) reduced the Spl
responsiveness of the BRLF1 promoter by 89%. In contrast,
mutation of the potential Spl-binding site (CCACCC) lo-
cated at -272 (positions -272 to -277), which was not
found to be important in the 5' deletional analysis, had no
significant effect on the Spl responsiveness of the BRLF1
promoter. Other than the mutation specifically abolishing the
proximal Spl motif, none of the site-directed mutations
significantly reduced Spl responsiveness in SL2 cells.
From the above results it is clear that the consensus
Spl-binding site located at -39 is required for the Spl
response of the BRLF1 promoter. Although we have not yet
determined the exact sequence (mapped by the 5' deletional
analysis) contributing to the Spl response in the -379 to
-575 region of BRLF1, it appears that both the proximal and
distal Spl-responsive regions are required for maximal Spl
transactivation of BRLF1.
Spl responsiveness can be transferred to a heterologous
promoter. Once we had determined that the region between
-30 and -182 in the BRLF1 promoter contains an Spl
response element, we also asked whether this region of the
promoter was sufficient to transfer Spl responsiveness to a
heterologous promoter. We inserted one copy of this se-
quence upstream of the adenovirus E1B TATA box in the
ElBCAT construct (48) (a gift from Katherine Martin). As
shown in Fig. 7, the E1B promoter alone is minimally
responsive to the Spl transcription factor. However, when
the -30 to -182 sequence of BRLF1 was inserted upstream
of the E1B TATA element, the promoter was activated
13-fold by cotransfection with Spl. The -30 to -182 region
of the BRLF1 promoter is therefore sufficient to transfer Spl
responsiveness to a heterologous promoter.
The Spl protein binds directly to the BRLF1 promoter. As
outlined above, our functional studies suggested that there
are two different Spl-responsive regions in the BRLF1
promoter: a proximal site from -39 to -44 containing the
consensus Spl motif (CCGCCC), and the -379 to -575
region. To confirm that the Spl protein, as expected, binds
directly to the BRLF1 promoter, we performed gel retarda-
tion assays. Binding studies were initially performed by
using commercially available purified Spl protein
(Promega). Purified Spl protein bound to a BRLF1 probe
containing the promoter sequences from -1 to -182, as well
as to a BRLF1 probe containing the sequences from -179 to
-575 (Fig. 8). Similar data were obtained with HeLa cell
J. VIROL.

















FIG. 6. Mapping the Spl-responsive regions in the BRLF1 promoter. The ability of Spl to activate a series of RpBSCAT deletion plasmids
in Drosophila SL2 cells was analyzed. The 5' deletions were constructed as shown in Fig. 1A, and the site-directed mutations were
constructed as shown in Fig. 1B. The results are presented as the average fold transactivation induced by Spl (versus the frameshift mutant
vector) relative to the Spl transactivation of the intact promoter construct (RpBSCAT). In this set of experiments, the average transactivation
induced by Spl on the parental RpBSCAT construct was 114-fold.
extracts as a source of protein; in these extracts both probes
were bound to proteins specifically inhibited by the Spl
sequence (data not shown; see Fig. 11). It thus appears that
there are at least two Spl-binding sites within the BRLF1
promoter.
We subsequently used methylation protection (1) to map
the proximal region of the BRLF1 promoter contacted by the
Spl-inhibited bands in HeLa cell extracts. Using a probe
containing the BRLF1 sequences from -1 to -182, we were
able to observe partial protection of the proximal Spl motif
in the bound probe, as shown in Fig. 9. We have not yet
mapped the precise sequence bound by Spl in the -182 to
-575 probe.
The proximal Spl-binding site is required for constitutive
activity in C-33 cells. The above results suggested that the
proximal Spl-binding site is required for efficient Spl acti-
vation in Drosophila cells. To determine whether this Spl
2.6%
motif is also required for efficient BRLF1 promoter activity
in C-33 cells, we examined the constitutive activity of the
series of site-directed BRLF1 mutants (Fig. 1B) in C-33
cells. In this set of experiments (Fig. 10), the C-33 cell
extracts were incubated overnight with [14C]chlorampheni-
col (in contrast to the experiment in Fig. 2, in which
incubations were performed for 1 h), resulting in a constitu-
tive level of RpBSCAT activity of 61%. The mutation
abolishing the proximal Spl motif (positions -39 to -44)
completely inhibited the constitutive activity of the RpB-
SCAT plasmid (relative to the negative control plasmid,
pBSCAT) in C-33 cells. Therefore it appears that the prox-
imal Spl site is required for maintaining the high constitutive
Protein - Purified Spi






FIG. 7. Spl responsiveness can be transferred to a heterologous
promoter. The BRLF1 promoter sequences from -30 to -182 were
inserted upstream of the E1B TATA box in the ElBCAT construct
(48) to create the ElBCAT-Spl construct. The constructs were
transfected into SL2 cells in the presence and absence of the Spl
expression vector. The E1B promoter by itself responds minimally
to the Spl factor. However, the -30 to -182 BRLF1 promoter





(- 1 to - 182)
FIG. 8. Purified Spl protein binds to the BRLF1 promoter.
Purified Spl protein (Promega) was incubated with P-labeled
probes containing the BRLF1 sequence from -1 to -182 or from
-179 to -575. Spl protein produced a retarded complex with both
probes, which was specifically inhibited by cold oligonucleotide
DNA containing the consensus Spl site but not by cold oligonucle-
otide containing the Apl-binding site.
Spl I- + I
El BCAT
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FIG. 9. Mapping of the proximal Spl-binding site in the BRLF1
promoter by methylation protection. A 32P-labeled probe containing
the BRLF1 promoter sequences from -1 to -182 was incubated
with HeLa cell nuclear extract and then treated with dimethyl
sulfate immediately prior to gel electrophoresis. The retarded bands
specifically inhibited by the Spl motif were removed separately (B)
from the free probe (F), cleaved with piperidine, and analyzed on a
sequencing gel. The area of partial protection is indicated next to the
sequencing gel (0).
activity of the BRLF1 promoter in C-33 cells. One other
mutation, which affected the -36 to -38 region of the
BRLF1 promoter, also abolished BRLF1 constitutive activ-
ity. Although this mutation (being adjacent to the Spi motif)
could potentially decrease Spi binding, our finding that
Spi-induced activation in Drosophila SL2 cells was not
significantly affected by this mutation suggests that another
cellular factor required for C-33 activity may bind to this
site. The four other mutations each moderately decreased
promoter activity in C-33 cells.
The level of Spl binding to the BRLF1 promoter is similar
in several cell types. Our initial analysis of BRLF1 promoter
activity in different cell types suggested that the BRLF1
promoter had constitutive activity in C-33 cells but had no
activity in Raji cells (Fig. 2). Given that the Spl-binding
motif was subsequently shown to be required for constitu-
tive BRLF1 promoter activity in C-33 cells, we examined
whether differences in the level of Spl binding to the BRLF1
promoter in C-33 and Raji cells could account for the
difference in constitutive promoter activity. We performed
gel retardation studies comparing the proteins binding to the
BRLF1 promoter in C-33, HeLa, and Raji cell extracts.
When we incubated protein extracts from each of these
three cell types with the -1 to -182 32P-labeled BRLF1
probe, we observed several retarded bands which were
specifically inhibited by cold oligonucleotide DNA contain-
ing the consensus Spl-binding site but not by cold DNA
containing the consensus Apl site (Fig. 11). Since the level
of Spl-inhibited binding to the BRLF1 promoter in each of
the three cell extracts was very similar, the low level of
BRLF1 activity in Raji cells may not be due to insufficient
Spl binding. A probe containing the -179 to -575 region of
the BRLF1 promoter was also shown to bind to Spl-
inhibited complexes which were present in equal amounts in
all three cell types (data not shown). Interestingly, the Raji
extracts were found to contain an increased level of an
additional gel-retarded band (complex A) binding to the -1
to -182 probe; this band was present in only minimal
amounts in the HeLa and C-33 extracts, suggesting that this
protein might serve to negatively regulate BRLF1 activity in
Raji cells. We have not yet identified the exact binding site of
this potential negative regulator of BRLF1.
DISCUSSION
The Epstein-Barr virus BZLF1 gene product is unique







FIG. 10. The proximal Spl motif is required for constitutive BRLF1 promoter activity in C-33 cells. A series of site-directed deletions of
the RpBSCAT construct was constructed as shown in Fig. 1, and the activities of these deletion constructs in the C-33 cells were compared.
The number above each bar represents the average percent activity relative to that of the parental RpBSCAT plasmid. The promoterless
negative control plasmid, pBSCAT, has 16% of the activity of RpBSCAT in this series of experiments. The BRLF1 promoter mutation
abolishing the proximal Spl motif (-39 to -44) reduced the level of BRLF1 activity to that of the promoterless construct. The mutant A36-38
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FIG. 11. Comparison of the level of Spl binding to the BRLF1
promoter mn different cell extracts. HeLa, C-33, and Raji cell
extracts were prepared by using a modification of the method of
Dignam et al. (14). A " P-labeled probe containing the BRLF1
promoter sequences from -1 to -182 was incubated with an equal
amount of protein from each extract. The amount of the retarded
complexes which were specifically inhibited by the Spl binding
sequence was similar in all three cell types. However, another
retarded band (complex A) was present at much higher levels in Raji
cells than in HeLa or C-33 cells.
latent infection to productive infection (8-10, 30, 57, 58, 66).
Latent viral infection in B cells can also be disrupted by a
variety of other compounds, including 12-O-tetradecanoyl-
phorbol-13-acetate (TPA), butyrate, and cross-linking sur-
face immunoglobulin (36, 52). Although it has been generally
assumed that these alternate methods of disrupting viral
latency are mediated by activation of the BZLF1 promoter
(23), it is equally plausible that disruption of viral latency in
certain situations is mediated by activation of the BRLF1
promoter. Overexpression of the bicistronic mRNA has not
yet been shown to disrupt viral latency. In principle, how-
ever, expression of the 2.8-kb RNA driven from the BRLF1
promoter should be sufficient to express both the Z and R
proteins, thus activating the lytic cycle. In addition, the
regulation of the BRLF1 promoter plays a key role in EBV
reactivation because this is the only known promoter to
direct transcription of the BRLF1 IE gene product (50).
Although the regulation of the BZLF1 promoter has been
relatively well studied (20, 21, 53), little has been published
regarding the regulation of the BRLF1 promoter. The
BZLF1 promoter has been shown to be activated by TPA
through TPA-responsive elements (20, 63) and to be auto-
regulated by the Z gene product through two Z-binding sites
(19, 70). In addition, a 48-bp negatively regulating cis ele-
ment has been located (between -433 and -386) in the
BZLF1 promoter; this element binds to the serum response
factor and another unidentified protein (53). Although the
BRLF1 promoter has been specifically shown not to be
activated by TPA treatment (63), essentially no information
has been previously published regarding the cellular factors
that do regulate BRLF1 activity. The possibility eximsts that
certain types of inducing agents preferentially activate the
BRLF1 promoter, whereas other inducing agents (such as
TPA) preferentially activate the BZLF1 promoter. Our stud-
ies examining the constitutive activity of the BRLF1 pro-
moter in different cell types demonstrated that the BRLF1
promoter is constitutively active in several different epithe-
lial cell lines but has no activity in a variety of different B-cell
lines. The finding of low constitutive BRLF1 promoter
activity in lymphoid cells correlates with the tendency of
EBV to remain latent in B cells and suggests that disruption
of viral latency in this cell type may require removal of a
negative regulator of BRLF1 promoter function.
This report provides the first identification of the cellular
Spl transcription factor as a positive regulator of BRLF1
function. Although a number of other viruses such as SV40,
herpes simplex virus type 1, and human immunodeficiency
virus have been previously shown to be regulated by the Spl
factor (16, 33), this is the first EBV promoter (to our
knowledge) shown to be regulated by Spl. In addition to
showing that the BRLF1 promoter is activated by the Spl
factor, we have specifically shown that the BZLF1 IE
promoter is not responsive to Spl. Although the Spl tran-
scription factor is expressed in a variety of different cell
lines, it has recently been shown that the level of Spl activity
is quite variable in different tissues (59) and that in certain
cell types the level of Spl activity can be limiting (60). Spl
activity has been recently shown to be positively regulated
by several factors, including the retinoblastoma gene prod-
uct (35, 39, 60). The ability of Spl to activate the BRLF1 but
not the BZLF1 promoter suggests that a cellular environ-
ment favoring high Spl activity might preferentially disrupt
viral latency through the BRLF1 (versus the BZLF1) pro-
moter.
Our analysis of the BRLF1 promoter sequences required
for Spl activation suggest that there are at least two Spl-
responsive elements in the promoter and that both of these
elements are required for efficient Spl activation. We have
specifically identified one of these elements as the consensus
Spl motif located at positions -39 to -44 in the promoter.
The other element has not yet been precisely identified, but
by 5' analysis it has been shown to reside between positions
-379 and -575. This region contains one copy of an
alternate Spl-binding site (CCACCC) recently identified in
the papillomavirus (44). Our demonstration that two differ-
ent Spl-binding sites are required for maximal BRLF1
activation by Spl is in keeping with recent results showing
that Spl bound to distal binding sites can interact synergis-
tically with Spl bound at proximal sites through direct
protein-protein contacts between Spl molecules (11, 54).
Although we have found that the BRLF1 promoter is
virtually silent in B cells, our gel retardation assays indicate
that the amount of Spl binding to the BRLF1 promoter is
essentially the same in Raji, HeLa, and C-33 extracts.
Therefore, it does not appear to be a relative lack of Spl
binding which accounts for the low constitutive activity of
the BRLF1 promoter in B cells. However, since a variety of
factors (such as the retinoblastoma gene product and the
human immunodeficiency virus TAT protein [35, 39]) have
recently been shown to modulate Spl transactivation func-
tion, it is possible that the availability of such Spl regulatory
factors accounts for the observed variability of BRLF1
activity. Interestingly, we have observed the presence of a
BRLF1 promoter-binding complex which is present in larg-
est amounts in Raji cells (in which there is no BRLF1
constitutive activity) and in smaller amounts in HeLa cells
(in which there is some constitutive activity) and is essen-
tially absent in C-33 cells (in which there is high constitutive
activity). This protein could potentially serve as a negative
regulator of BRLF1 function, and its presence in larger
amounts in Raji extracts may account for the total loss of
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BRLF1 constitutive activity. The binding site and nature of
this protein will be the focus of subsequent studies.
Unlike the findings of another group (63), we have been
unable to demonstrate that the Z gene product significantly
activates the BRLF1 promoter in any cell type. As reported
previously (63), we also found that the Z protein binds
directly to the BRLF1 promoter (unpublished data). The
reasons for the discrepancy between our own results and
those previously reported are not clear. One possibility is
that our Z expression vectors make significantly different
amounts of protein. The effect of Z on BRLF1 promoter
function may be dose dependent, with activation occurring
at lower doses of Z and repression occurring at high doses.
The proximal Z-binding site overlaps the CCAAT box,
which, from our mutational analysis, has some effect on
constitutive BRLF1 promoter activity in C-33 cells. The
sequences between -36 and -38 (adjacent to the proximal
Z-binding site) were also shown by our mutational analysis
to be essential for constitutive BRLF1 promoter activity,
and Z binding could potentially interfere with binding by an
essential cellular factor to this site. In addition, the proximal
Z-binding site is near the proximal Spl-binding site and
could potentially interfere with Spl binding. Further studies
are necessary to determine whether both the Spl and Z
factors can simultaneously bind to the BRLF1 promoter and,
if so, whether such binding results in synergistic (versus
antagonistic) activation of BRLF1.
As previously reported (63), we have also shown that the
R gene product can activate its own promoter. In this report,
we have extended the analysis of R transactivation of the
BRLF1 promoter by showing that the R protein does not
bind directly to the BRLF1 promoter. For two other EBV
promoters known to be activated by the R transactivator,
BMLF1 (27, 36) and DR (28), it has been shown that the R
protein binds directly to these promoters and that this
binding is required for R transactivation. Our finding that the
R protein can activate the BRLF1 promoter through a
nonbinding mechanism is the first suggestion that the R
protein may activate EBV promoters by more than one
mechanism, one involving direct binding and the other being
mediated indirectly through modulation of cellular transcrip-
tion factors. We have recently found that the R transactiva-
tor also activates the c-myc promoter through an apparently
indirect mechanism (29). Although we have not yet mapped
the region of the BRLF1 promoter required for R response,
it is possible that R activates the BRLF1 promoter through
modulation of Spl activity. The SV40 T antigen has been
recently shown to activate certain promoters through induc-
tion of cellular Spl activity (60).
In conclusion, we have shown that the cellular factor Spl
activates the BRLF1 promoter but not the BZLF1 promoter.
We have identified a binding site for Spl in this promoter and
shown that mutation of this site leads to loss of constitutive
promoter activity and response to Spl. The activation of the
BRLF1 promoter by Spl could be a potential mechanism for
disruption of viral latency.
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